化疗序贯EGFR-TKIs治疗晚期非小细胞肺癌的机制及疗效

随着肿瘤分子生物学研究的发展,表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)在晚期非小细胞肺癌治疗中占有重要地位,特别针对于EGFR突变型患者.但基于分子靶向药物并未明显改善患者的总生存时间及出现获得性耐药问题,如何将传统化疗药物与靶向药物有机结合延长晚期患者的总生存时间受到广泛关注.化疗序贯EGFR-TKIs模式被证实为其中一项颇有前景的治疗策略.本文将结合相关研究对化疗序贯EGFR-TKIs治疗晚期非小细胞肺癌(NSCLC)的机制及疗效进行综述.

Mechanism and effect of intercalated therapy with chemotherapy and EGFR-TKIs for advanced NSCLC patients

With the development of oncology molecular biology,epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) has been used more widely for the treatment of advanced non-small cell lung cancer,especially for the EGFR mutated patients.However,despite the positive results of these targeting agents in progression-free survival,significantly improving overall survival and overcoming acquired resistance to EGFR-TKIs after the initial response remains an issue.How to combine organically conventional cytotoxic chemotherapy with EGFR-TKIs becomes the focus.It has been demonstrated that intercalated therapy with chemotherapy and EGFR-TKIs is a promising treatment strategy.This article reviews the research progress and clinic application of intercalated therapy with chemotherapy and EGFR-TKIs.